Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Profit After Tax (2016 - 2025)

Ocular Therapeutix has reported Profit After Tax over the past 13 years, most recently at -$64.7 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$64.7 million for Q4 2025, down 33.62% from a year ago — trailing twelve months through Dec 2025 was -$265.9 million (down 37.43% YoY), and the annual figure for FY2025 was -$265.9 million, down 37.43%.
  • Profit After Tax for Q4 2025 was -$64.7 million at Ocular Therapeutix, up from -$69.4 million in the prior quarter.
  • Over the last five years, Profit After Tax for OCUL hit a ceiling of $3.1 million in Q1 2021 and a floor of -$69.4 million in Q3 2025.
  • Median Profit After Tax over the past 5 years was -$26.7 million (2022), compared with a mean of -$30.9 million.
  • Biggest five-year swings in Profit After Tax: skyrocketed 122.25% in 2021 and later plummeted 6972.29% in 2024.
  • Ocular Therapeutix's Profit After Tax stood at -$3.8 million in 2021, then crashed by 303.69% to -$15.5 million in 2022, then crashed by 88.01% to -$29.2 million in 2023, then crashed by 65.6% to -$48.4 million in 2024, then crashed by 33.62% to -$64.7 million in 2025.
  • The last three reported values for Profit After Tax were -$64.7 million (Q4 2025), -$69.4 million (Q3 2025), and -$67.8 million (Q2 2025) per Business Quant data.